WESTMINSTER, Colo., Nov. 5 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today reported financial results
for the third quarter of 2007. For the three months ended September
30, 2007, the Company reported a net loss of $9.3 million, or
($0.14) per share. This compares to a net loss of $8.1 million, or
($0.15) per share, for the third quarter of 2006. For the nine
months ended September 30, 2007, the Company reported a net loss of
$28.1 million, or ($0.43) per share, compared to a net loss of
$22.1 million, or ($0.40) per share for the same period last year.
For the nine months ended September 30, 2007, net cash used in
operating activities was $22.5 million. Cash, cash equivalents and
investments in marketable securities as of September 30, 2007 were
$63.4 million. "With five PDX trials ongoing and two additional
studies scheduled to begin in the near term, we continue to make
important progress advancing the development of PDX in hematologic
malignancies and solid tumors," stated Paul L. Berns, President and
Chief Executive Officer of Allos. "PROPEL, our pivotal Phase 2
trial of PDX in patients with relapsed or refractory peripheral
T-cell lymphoma, is ahead of schedule with completion of patient
enrollment expected in the second quarter of 2008. We look forward
to providing future updates regarding PDX's clinical profile and
potential commercial opportunities." Pipeline Development Update:
PDX (pralatrexate) PDX is a novel, small molecule chemotherapeutic
agent that inhibits dihydrofolate reductase, or DHFR, a folic acid
(folate)-dependent enzyme involved in the building of nucleic acid,
or DNA, and other processes. PDX is an investigational drug
currently under evaluation in patients with lymphoma and non-small
cell lung cancer (NSCLC). PROPEL In September 2007, the Company
announced the completion of pre-planned interim analyses of patient
response and safety data from the Company's pivotal Phase 2 PROPEL
trial of PDX in patients with relapsed or refractory peripheral
T-cell lymphoma (PTCL). Results of the interim analysis of patient
response data exceeded the pre-specified threshold for continuation
of the trial, which required a minimum of four responses (complete
or partial) out of the first 35 evaluable patients, as determined
by independent oncology review. In addition, an independent Data
Monitoring Committee (DMC) completed an interim analysis of the
safety data from the first 35 evaluable patients and recommended
that the trial continue per the protocol. In accordance with the
trial protocol, the DMC will conduct another interim analysis of
safety data from the first 65 evaluable patients. The Company
expects to report the outcome of the 65-patient safety analysis by
the end of 2007 and complete enrollment in the trial in the second
quarter of 2008. PDX in CTCL In August 2007, the Company announced
the initiation of patient enrollment in a Phase 1, open-label,
multi-center study of PDX with vitamin B12 and folic acid
supplementation in patients with relapsed or refractory cutaneous
T-cell lymphoma (CTCL). Up to 56 evaluable patients will be
enrolled in the study with the objective of determining the optimal
dose and safety profile of PDX in this population. A total of 20 of
these patients will be enrolled at the determined optimal dose and
schedule. PDX in NSCLC (Phase 1) In October 2007, data from the
Company's Phase 1 dose ranging study of PDX with vitamin B12 and
folic acid supplementation in patients with previously treated
advanced NSCLC were presented at the 2007 AACR-NCI-EORTC
conference. In this study, a total of 22 patients with relapsed or
refractory NSCLC were treated at doses of 150 to 325 mg/m2 of PDX.
The maximum tolerated dose (MTD) was determined to be 270 mg/m2,
which is nearly twice that observed in a previous Phase 1 study in
which PDX was administered without vitamin supplementation.
Clinically significant radiologic responses were observed. Greater
than 50% of patients (13/22) received 2 or more prior treatment
regimens. Based on PDX clinical experience to date, the Company
plans to initiate a randomized Phase 2 study of PDX in patients
with NSCLC. PDX in NHL (Phase 1/2) In October 2007, additional
interim data from the Company's on-going Phase 1/2 study of PDX in
patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease
were presented at the 2007 AACR-NCI-EORTC conference. Responses
were observed in 14 of 26 (54%) evaluable patients with T-cell
lymphoma, with the duration of response typically exceeding the
previously administered line of chemotherapy. No major safety
concerns were identified in this heavily pre-treated population.
These results are consistent with the interim data presented at the
2006 American Society of Hematology (ASH) meeting. PDX In Vivo and
In Vitro In October 2007, results from a Company-sponsored
pre-clinical study that investigated the mechanism of action of PDX
and its differences from other antifolates, and compared the in
vivo activity of PDX, methotrexate (MTX) and Alimta(R) against two
NSCLC models were presented at the 2007 AACR-NCI-EORTC conference.
The results suggest that PDX is mechanistically different from MTX
and Alimta and that these differences may be due to enhanced uptake
of PDX into the tumor cell and/or greater intracellular
accumulation and polyglutamylation, resulting in greater inhibition
of dihydrofolate reductase (DHFR). In addition, PDX induced greater
tumor regression compared to MTX or Alimta in two human NSCLC
xenograft models, including the highly aggressive H460 model. RH1
RH1 is a novel small molecule chemotherapeutic agent that is
bioactivated by the enzyme DT-diaphorase, or DTD, which is
over-expressed in many tumors, including lung, colon, breast and
liver tumors. The Company expects to initiate a Phase 1 study of
RH1 in patients with advanced solid tumors in the fourth quarter of
2007. Conference Call The Company will host a conference call to
review its third quarter results on Monday, November 5, 2007, at
8:30 AM ET. The dial in number for U.S. residents to participate is
888-339-9446. International callers should dial 480-629-9562.
Participants should reference the Allos Therapeutics conference
call. Conference Call Replay An audio replay of the conference call
will be available until 11:59 PM ET on Friday, November 16, 2007.
To access the replay, please dial 800-406-7325 (domestic) or
303-590-3030 (international). The access code is 3789950. Webcast
The Company will also hold a live webcast of the conference call.
The webcast will be available from the homepage and the
investors/media section of the Company's website at
http://www.allos.com/ and will be archived for 30 days. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in
a pivotal Phase 2 (PROPEL) trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The PROPEL trial is being
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment, or SPA
process. The Company is also investigating PDX in patients with
non-small cell lung cancer and a range of other lymphoma sub-types.
The Company's other product candidate is RH1, a targeted
chemotherapeutic agent for which the Company expects to initiate a
Phase 1 study in patients with advanced solid tumors in the fourth
quarter of 2007. For additional information, please visit the
Company's website at http://www.allos.com/. Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the Company's projected
timelines for the performance of the 65 patient safety assessment
and completion of enrollment of the PROPEL trial, the Company's
intent to initiate a Phase 2 study of PDX in patients with NSCLC,
and other statements which are other than statements of historical
facts. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "expects,"
"intends," "plans," anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar
terminology or the negative of these terms, but their absence does
not mean that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others: that the Company may experience difficulties or
delays in the initiation, progress or completion of its clinical
trials, whether caused by competition, adverse events,
investigative site initiation rates, patient enrollment rates,
regulatory issues or other factors; and that the Company's clinical
trials may not demonstrate the safety and efficacy of the Company's
product candidates in their target indications. Even if clinical
trials demonstrate the safety and efficacy of the Company's product
candidates, regulatory authorities may not approve such product
candidates, the Company may not be able to successfully market such
product candidates, or the Company may face post-approval problems
that require the withdrawal of its product candidates from the
market. In addition, the Company may lack the financial resources
and access to capital to fund planned or future clinical trials of
its product candidates, or to continue evaluating their therapeutic
utility in other potential indications. Additional information
concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking
statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2006, and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law. ALLOS THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS (in thousands ~ except share and
per share information) (unaudited) Three-months ended Nine-months
ended September 30, September 30, 2006 2007 2006 2007 Operating
expenses: Research and development $4,210 $4,395 $10,970 $12,045
Clinical manufacturing 486 1,506 1,438 4,038 Marketing, general and
administrative 3,895 4,241 10,560 14,503 Restructuring and
separation costs - - 646 - Total operating expenses 8,591 10,142
23,614 30,586 Loss from operations (8,591) (10,142) (23,614)
(30,586) Interest and other income, net 480 844 1,471 2,526 Net
loss $(8,111) $(9,298) $(22,143) $(28,060) Net loss per share:
basic and diluted $(0.15) $(0.14) $(0.40) $(0.43) Weighted average
shares outstanding: basic and diluted 55,196,369 66,042,023
55,126,488 64,627,285 ALLOS THERAPEUTICS, INC. CONDENSED BALANCE
SHEETS (in thousands) (unaudited) December 31, September 30, 2006
2007 ASSETS Cash, cash equivalents and investments in marketable
securities $32,796 $63,370 Other assets 2,982 3,525 Property and
equipment, net 604 543 Total assets $36,382 $67,438 LIABILITIES AND
STOCKHOLDERS' EQUITY Liabilities $6,832 $8,170 Stockholders' equity
29,550 59,268 Total liabilities and stockholders' equity $36,382
$67,438 DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole,
Vice President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024